NASDAQ:OVID - Ovid Therapeutics Inc.
$1.77
 $-0.02
-1.12%
4:00PM EDT
2019-04-18
Ovid Therapeutics Inc. (Ovid), incorporated on April 1, 2014, is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Companys second lead drug candidate is OV935. OV101The Company is developing OV101 for the treatment of Angelman syndrome and Fragile X syndrome. OV101 is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. The Company has commenced a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. OV101, has commenced a Phase II trial, which is primarily a safety trial that is designed to provide proof-of-concept on efficacy parameters, in adults with Angelman syndrome.OV935The Company is developing OV935 in collaboration with Takeda Pharmaceutical Company Limited (Takeda) for the treatment of rare epileptic encephalopathies. OV935 is a potent, highly selective inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H).The Company competes with SAGE Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc., Zogenix, Inc., GW Pharmaceuticals plc, Sage Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc., Insys Therapeutics, Inc. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  OVID     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 03   203. 85   241. 91  
42 stocks rank:  4. 36 K 1. 44 K 1. 05 K
# analyst opinions:  5. 00   14. 51   13. 97  
mean recommendation:  1. 60   2. 09   2. 01  

quick ratio:  4. 69   5. 27   1. 81  
current ratio:  5. 00   5. 62   2. 25  

target price low:  2. 23   84. 80   115. 21  
target price avg:  1. 34   111. 51   137. 51  
target price high:  2. 70   135. 81   157. 84  
1-yr high:  11. 11   114. 23   138. 78  
last close:  1. 77   87. 66   116. 69  
50-day avg:  2. 00   95. 54   123. 44  
200-day avg:  4. 68   94. 25   121. 11  
1-yr low:  1. 76   72. 78   98. 34  
volume:  401. 83 K 4. 11 M 8. 07 M
50-day avg volume:  395. 68 K 2. 76 M 5. 02 M
200-day avg volume:  159. 05 K 2. 92 M 4. 59 M

1-day return:  -1. 12 % -0. 41 % 0. 07 %
this week return:  -3. 28 % -5. 74 % -4. 11 %
12-wk return:  -45. 87 % 1. 61 % -0. 05 %
52-wk return:  -82. 19 % 3. 12 % 8. 78 %

enterprise value (EV):  26. 91 M 48. 94 B 114. 64 B
market cap:  68. 41 M 43. 07 B 104. 73 B
EBITDA:  -52. 79 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -0. 51   4. 22   12. 73  
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -51. 98 M 2. 20 B 4. 20 B

shares outstanding:  38. 65 M 571. 70 M 1. 24 B
shares:  19. 84 M 571. 81 M 1. 23 B
shares short:  303. 22 K 10. 17 M 13. 00 M
shares short prior month:  167. 55 K 9. 54 M 17. 33 M
short ratio:  1. 58   5. 41   3. 28  
short % of float:  2. 04 % 5. 45 % 2. 38 %
total cash/share:  1. 07   11. 14   9. 33  
total cash:  41. 50 M 6. 71 B 7. 15 B
free cash flow:  -24. 71 M 3. 58 B 2. 96 B
operating cash flow:  -45. 56 M 4. 15 B 4. 30 B

book value:  1. 57   12. 78   26. 92  
price/book:  1. 12   3. 06   -1. 74  
operating margins:  0. 00 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  -36. 13 % --- ---
1-yr mean volatility:  -0. 55 % 0. 03 % 0. 04 %

1-yr EPS:  -2. 11   2. 40   4. 10  
forward EPS:  -2. 35   3. 97   7. 13  
P/E:  -0. 84   13. 63   22. 72  
forward P/E:  -0. 75   -15. 95   13. 99  
PE/G:  0. 02   -1. 65   -1. 32  
growth:  -37. 96 % 127. 12 % 29. 61 %
earnings high:  -0. 31   1. 00   1. 66  
earnings avg:  -0. 42   0. 77   1. 53  
earnings low:  -0. 54   0. 50   1. 39  
revenue high:  -0. 00   2. 68 B 10. 78 B
revenue avg:  -0. 00   2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -48. 26 % -2. 75 % 4. 55 %
return on equity:  -85. 04 % -18. 45 % 5. 46 %

beta (1yr vs S&P500):  1. 14   1. 25   0. 93  
sharpe (1yr):  -1. 77   0. 37   0. 70  

held % insiders:  41. 41 % 6. 39 % 3. 38 %
held % institutions:  25. 99 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : OVID
.        + 0 =             0 :: INITIAL WEIGHT
.    + 30.03 =         30.03 :: spline projection addition
.    x 1.431 =        42.986 :: industry recommendation factor
.    x 2.622 =       112.727 :: symbol recommendation factor
.    x 0.995 =       112.183 :: return on assets factor
.    x 0.991 =       111.228 :: return on equity factor
.     x 2.89 =       321.439 :: current ratio factor
.    x 1.127 =       362.365 :: quick ratio factor
.    x 1.278 =        463.05 :: short ratio factor
.    x 2.011 =       931.307 :: price-to-book factor
.    x 2.163 =      2014.666 :: P/E weight
.    x 2.209 =      4450.314 :: PE/G factor
.    x 1.597 =      7105.627 :: beta factor
.    x 0.318 =      2259.448 :: sharpe factor
.     x 1.53 =      3456.905 :: target low factor
.    x 0.913 =      3154.903 :: target mean factor
.    x 1.072 =       3383.59 :: target high factor
.     x 1.31 =      4432.123 :: industry 2-weeks return factor
.    x 0.952 =      4217.922 :: overall "drift" factor
.    x 0.998 =      4211.381 :: largest single-day jump factor
.    x 0.065 =       273.289 :: low price factor
.      x 1.0 =       273.244 :: factor hist industry gain for week 16
.   cubeRoot =         6.489 :: reduced to standardize
.   - 24.872 =          0.03 :: add/subtract for performance
.                       0.03 :: FINAL WEIGHT for NASDAQ:OVID


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org